Pergolide in Parkinson's disease.

Abstract

Twenty-two patients received pergolide mesylate for Parkinson's disease for one year. Improvement was maximal at six months, but average functional scores were still better at 12 months than at pretreatment evaluation. On-off fluctuations were reduced in severity, and two of 18 patients experienced full resolution. Pergolide is an effective and safe ongoing medication for Parkinson's disease.

• Authors: C G Goetz, C M Tanner, R Glantz, H L Klawans
• Journal: Archives of neurology (Arch Neurol) Vol. 40 Issue 13 Pg. 785-7 (Dec 1983) ISSN: 0003-9942 [Print] United States
• PMID: 6639407 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Ergolines
• Pergolide

Topics

• Aged
• Ergolines (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Pergolide